← All trials
NCT05367089
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 22, 2022
- Primary completion
- Apr 22, 2026
- Completion date
- Apr 22, 2027
- First posted
- May 10, 2022
- Last posted
- Dec 19, 2022
- Enrollment
- 252
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Maastricht UniversityLead sponsor
- Zuyderland Medisch CentrumCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.